首页 > 市场调查报告书 > 医疗设备

泌尿科

市场调查报告书

商品编码

1601793

女性压力性尿失禁治疗设备市场 - 全球产业规模、份额、趋势、机会和预测，按产品类型、最终用户、地区和竞争细分，2019-2029F

Female Stress Urinary Incontinence Treatment Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By End-user, By Region and Competition, 2019-2029F

出版日期: 2024年11月30日 | 出版商:

TechSci Research | 英文 183 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023年，全球女性压力性尿失禁治疗设备市场价值为7.7218亿美元，预计2029年将达到11.0777亿美元，预测期内复合年增长率为6.34%。

市场概况
预测期	2025-2029
2023 年市场规模	77218万美元
2029 年市场规模	110777万美元
2024-2029 年复合年增长率	6.34%
成长最快的细分市场	尿道吊带
最大的市场	北美洲

由于女性压力性尿失禁 (SUI) 盛行率不断上升、医疗技术的进步以及对可用治疗方案的认识不断提高，全球女性压力性尿失禁 (SUI) 治疗设备市场正在大幅增长。压力性尿失禁是一种因咳嗽、打喷嚏或运动等体力活动导致不自主尿液漏出的疾病，会严重影响生活品质。由于老化、肥胖和生育等因素，发病率不断上升，推动了对有效治疗解决方案的需求。市面上的主要设备包括阴道吊带、人工尿道括约肌和电刺激设备。可调节和先进吊带的新兴创新进一步改善了患者的治疗效果，鼓励了采用。电刺激装置作为非手术替代方案越来越受到关注，吸引了寻求保守治疗选择的女性。

主要参与者正大力投资研发，旨在推出创新的、以患者为中心的解决方案。与医疗保健提供者的合作伙伴关係和策略性收购正在塑造市场动态。然而，设备相关併发症、手术介入的高成本以及资源匮乏地区获得先进治疗的机会有限等挑战构成了障碍。在技术进步、诊断率提高以及改善全球女性健康的努力的支撑下，该市场有望显着增长。这条轨迹强调了治疗设备在提高受压力性尿失禁影响的女性的生活品质方面的关键作用。

主要市场驱动因素

女性压力性尿失禁的盛行率不断上升

SUI 盛行率的上升增加了对各种治疗设备的需求。其中包括阴道吊带、骨盆底电刺激系统和尿道填充剂，它们共同提供不同患者需求的手术和非手术解决方案。医疗技术的进步也引入了微创和门诊手术，进一步吸引了寻求有效且方便的治疗选择的患者。一项干预性研究（ClinicalTrials.gov：NCT03978741）评估了 Yoni.Fit 对于符合特定诊断标准的 18 岁及以上女性临时控制压力性尿失禁 (SUI) 的安全性和有效性。共有 58 位患者被随机分配使用 Yoni.Fit 或比较设备。主要终点是第 21 天的反应率，定义为与基线相比，12 小时垫重量平均减少 50%。结果显示，更多使用 Yoni.Fit 的患者实现了具有临床意义的护垫重量减轻（53% 对比 23.3%；P = 0.013）。此外，96.3% 的 Yoni.Fit 使用者的 SUI 发作次数减少了 50% 以上，而对照组为 27.2%（P< 0.001）。 Yoni.Fit 组中更多的患者报告「明显改善」或更好（P = 0.001）。最常见的不良事件是阴道不适，没有严重不良事件的通报。此外，公众意识活动和健康教育计划正在阐明 SUI 及其治疗方法，减少耻辱并鼓励更多女性寻求专业帮助。这种日益增长的认识，加上创新治疗设备的出现，使市场进一步扩大，满足了越来越多受影响人群的需求。

微创治疗技术的进步

微创治疗技术的进步已成为全球女性压力性尿失禁（SUI）治疗设备市场成长的关键驱动力。传统的外科手术虽然有效，但通常需要较长的恢復时间，并且出现感染和组织损伤等併发症的风险较高。现代创新，例如无张力阴道吊带和经闭孔胶带系统，透过提供侵入性显着降低的高效解决方案，改变了这些手术。这些设备旨在提供更快的恢復时间、减少术后疼痛并降低併发症的风险，从而提高患者的舒适度和治疗效果。

这些处理方法最显着的进步之一在于所使用的材料。现代吊带装置现在采用轻质、生物相容性网状材料，可提供耐用性，同时最大限度地减少组织刺激。材料的这种演变提高了患者满意度，减少了长期併发症，并有助于提高整体成功率。这些创新也使程序对医疗保健提供者更具吸引力，使他们能够提供量身定制的、针对患者的解决方案。同时，非手术治疗替代方案也取得了显着进展。例如，电刺激设备现在具有更精确的瞄准机制，可以有效增强骨盆底肌肉，而无需侵入性手术。这些技术对于寻求强度较低的治疗方案的女性或禁忌手术的女性特别有益。

医疗器材公司对研发的持续关注确保了持续的创新。这些努力不仅扩大了治疗选择的范围，而且还提高了设备的安全性、有效性和可负担性。数位健康技术的集成，例如远端监控和基于应用程式的设备使用指导，使治疗变得更加用户友好和方便。由于这些技术进步同时满足了手术和非手术需求，因此提高了患者和医疗保健提供者的采用率，最终促进了全球女性 SUI 治疗设备市场的成长。

对 SUI 治疗的认识与接受度不断提高

人们对压力性尿失禁（SUI）治疗的认识和接受度不断提高，已成为推动全球市场成长的重要因素。从历史上看，社会耻辱和对 SUI 的了解有限，使许多女性不愿寻求专业帮助，从而导致这种情况得不到治疗并影响了她们的生活品质。然而，多年来，医疗保健提供者、非政府组织和设备製造商的共同努力已经显着改变了这种说法。教育活动在减少与 SUI 相关的耻辱方面发挥了至关重要的作用。这些倡议强调了这种疾病的流行程度、其对日常生活的影响以及及时寻求治疗的重要性。透过使有关 SUI 的讨论正常化，这些努力使女性能够认识到这种情况是一个可以控制的医疗问题，而不是个人的失败。医疗保健提供者越来越强调早期介入的好处，例如预防併发症和改善生活质量，进一步鼓励女性寻求治疗。

数位平台的兴起也彻底改变了 SUI 资讯的取得方式。包括网站、社交媒体和远端咨询服务在内的线上资源使女性更容易了解自己的病情并探索可用的治疗方法。设备製造商和医疗保健组织提供的互动式工具和教育内容正在弥合知识差距，使患者能够做出明智的决策。此外，社会对女性健康的态度也发生了变化，促进了对 SUI 等问题的公开讨论。这种转变，加上健康素养的提高，导致寻求专家咨询和探索从微创外科手术到非侵入性治疗等治疗方案的女性人数激增。

主要市场挑战

先进处理设备成本高

市场竞争激烈，缺乏差异化

主要市场趋势

增加研发投资

扩大新兴市场的医疗保健基础设施

细分市场洞察

产品类型见解

区域洞察

Market Overview
Forecast Period	2025-2029
Market Size 2023	USD 772.18 Million
Market Size 2029	USD 1107.77 Million
CAGR 2024-2029	6.34%
Fastest Growing Segment	Urethral Slings
Largest Market	North America

The Global Female Stress Urinary Incontinence (SUI) Treatment Devices Market is witnessing substantial growth, driven by the increasing prevalence of SUI among women, advances in medical technologies, and growing awareness of available treatment options. Stress urinary incontinence, a condition characterized by involuntary urine leakage due to physical activities such as coughing, sneezing, or exercising, significantly impacts quality of life. The rising incidence, attributed to factors such as aging, obesity, and childbirth, is propelling the demand for effective treatment solutions. Key devices in the market include vaginal slings, artificial urinary sphincters, and electrical stimulation devices.Vaginal slings, particularly minimally invasive tension-free procedures, dominate the market due to their high success rates and shorter recovery times. Emerging innovations in adjustable and advanced slings have further enhanced patient outcomes, encouraging adoption. Electrical stimulation devices are gaining traction as non-surgical alternatives, appealing to women seeking conservative treatment options.

Key players are heavily investing in research and development, aiming to introduce innovative, patient-centric solutions. Partnerships with healthcare providers and strategic acquisitions are shaping market dynamics. However, challenges such as device-related complications, high costs of surgical interventions, and limited access to advanced treatments in low-resource settings pose barriers. The market is poised for significant growth, underpinned by technological advancements, increased diagnosis rates, and efforts to improve women's health worldwide. This trajectory underscores the critical role of treatment devices in enhancing the quality of life for women affected by stress urinary incontinence.

Key Market Drivers

Rising Prevalence of Stress Urinary Incontinence Among Women

The rising prevalence of stress urinary incontinence (SUI) among women globally is a critical factor driving the market's growth. SUI, characterized by involuntary leakage of urine during physical activities such as coughing, sneezing, or exercising, is often caused by the weakening of pelvic floor muscles and urethral support. Key contributing factors include aging, childbirth, menopause, obesity, and chronic medical conditions. With an increasingly aging population, particularly in developed nations, the number of women affected by SUI is steadily rising. Interestingly, the condition is no longer confined to older demographics. Sedentary lifestyles, obesity, and high levels of physical strain are contributing to a noticeable increase in cases among younger women. This shift highlights the condition's evolving dynamics and underscores the growing need for effective treatment options. Women experiencing SUI often face reduced quality of life, embarrassment, and potential social isolation, leading to greater awareness and a proactive approach to seeking medical solutions.

The heightened prevalence of SUI has bolstered demand for a variety of treatment devices. These include vaginal slings, pelvic floor electrical stimulation systems, and urethral bulking agents, which collectively offer surgical and non-surgical solutions tailored to different patient needs. Advancements in medical technology have also introduced minimally invasive and outpatient procedures, further appealing to patients seeking effective yet convenient treatment options. An interventional study (ClinicalTrials.gov: NCT03978741) assessed the safety and efficacy of Yoni.Fit for temporarily managing stress urinary incontinence (SUI) in women aged 18 and older, who met specific diagnostic criteria. A total of 58 patients were randomized to use Yoni.Fit or a comparator device. The primary endpoint was a responder rate at day 21, defined as a 50% reduction in mean 12-hour pad weight compared to baseline. Results showed significantly more patients using Yoni.Fit achieved clinically meaningful reductions in pad weight (53% vs. 23.3%; P = 0.013). Additionally, 96.3% of Yoni.Fit users experienced a >50% reduction in SUI episodes, compared to 27.2% in the comparator group (P < 0.001). More patients in the Yoni.Fit group reported being "much improved" or better (P = 0.001). The most common adverse event was vaginal discomfort, with no serious adverse events reported. In addition, public awareness campaigns and health education programs are shedding light on SUI and its treatment, reducing stigma and encouraging more women to seek professional help. This growing recognition, coupled with the availability of innovative treatment devices, positions the market to expand further as it addresses the needs of an increasingly affected population.

Advancements in Minimally Invasive Treatment Technologies

Advancements in minimally invasive treatment technologies have become a pivotal driver in the growth of the global female stress urinary incontinence (SUI) treatment devices market. Traditional surgical interventions, while effective, often involve extensive recovery times and carry higher risks of complications such as infections and tissue damage. Modern innovations, such as tension-free vaginal slings and transobturator tape systems, have transformed these procedures by providing highly effective solutions that are significantly less invasive. These devices are designed to offer faster recovery periods, reduced postoperative pain, and lower risks of complications, thereby enhancing patient comfort and outcomes.

One of the most notable advancements in these treatments lies in the materials used. Modern sling devices now utilize lightweight, biocompatible meshes that provide durability while minimizing tissue irritation. This evolution in materials has improved patient satisfaction, reduced long-term complications, and contributed to better overall success rates. These innovations have also made procedures more appealing to healthcare providers, enabling them to offer tailored, patient-specific solutions. In parallel, non-surgical treatment alternatives have also advanced significantly. Electrical stimulation devices, for instance, now feature more precise targeting mechanisms that strengthen pelvic floor muscles effectively without invasive procedures. These technologies have been particularly beneficial for women seeking less intensive treatment options or for those contraindicated for surgery.

The continued focus on research and development by medical device companies ensures a consistent pipeline of innovations. These efforts have not only expanded the range of treatment options but have also enhanced the safety, efficacy, and affordability of devices. The integration of digital health technologies, such as remote monitoring and app-based guidance for device use, has made treatments more user-friendly and accessible. As these technological advancements address both surgical and non-surgical needs, they are driving higher adoption rates among patients and healthcare providers alike, ultimately fostering growth in the global female SUI treatment devices market.

Growing Awareness and Acceptance of SUI Treatments

The growing awareness and acceptance of stress urinary incontinence (SUI) treatments have become a vital factor in driving the global market's growth. Historically, social stigma and limited knowledge about SUI discouraged many women from seeking professional help, leaving the condition untreated and impacting their quality of life. However, over the years, concerted efforts by healthcare providers, non-governmental organizations, and device manufacturers have significantly shifted this narrative. Educational campaigns have played a crucial role in reducing the stigma associated with SUI. These initiatives highlight the prevalence of the condition, its impact on daily life, and the importance of seeking timely treatment. By normalizing discussions around SUI, these efforts have empowered women to recognize the condition as a manageable medical issue rather than a personal failing. Healthcare providers have increasingly emphasized the benefits of early intervention, such as preventing complications and improving quality of life, further encouraging women to seek treatment.

The rise of digital platforms has also revolutionized access to information about SUI. Online resources, including websites, social media, and teleconsultation services, have made it easier for women to learn about their condition and explore available treatments. Interactive tools and educational content provided by device manufacturers and healthcare organizations are bridging the knowledge gap, enabling informed decision-making among patients. Additionally, societal attitudes toward women's health have evolved, promoting open discussions about issues like SUI. This shift, coupled with improved health literacy, has led to a surge in the number of women seeking consultations with specialists and exploring treatment options, ranging from minimally invasive surgical procedures to non-invasive therapies.

Key Market Challenges

High Costs of Advanced Treatment Devices

The high costs associated with advanced female stress urinary incontinence (SUI) treatment devices pose a significant barrier to market growth. Devices such as electrical stimulation units and biofeedback systems are lauded for their effectiveness and convenience, but their premium pricing makes them inaccessible to a large segment of the population, particularly in low- and middle-income regions. Many patients in these areas face economic constraints that prevent them from considering such high-cost solutions. In developed markets, the issue is compounded by the limited coverage offered by health insurance providers. Non-surgical treatments are often considered elective, leading to partial reimbursement or outright exclusion from insurance plans, further increasing out-of-pocket expenses for patients.

Healthcare providers are also impacted by the high costs of these devices. Budget restrictions, particularly in public healthcare institutions or smaller private clinics, deter providers from investing in advanced equipment, limiting the availability of these treatments to patients. This financial hurdle restricts market penetration, as even highly innovative products struggle to achieve widespread adoption due to their prohibitive costs. Manufacturers face the dual challenge of innovating while maintaining affordability, which is critical for expanding their consumer base. Without addressing these cost-related concerns, the adoption of advanced female SUI treatment devices may remain confined to affluent regions, stalling global market growth and leaving many patients without access to effective care.

Intense Market Competition and Lack of Differentiation

The global female stress urinary incontinence (SUI) treatment devices market is facing intense competition, with a growing number of manufacturers offering similar products. This saturation creates significant challenges for companies trying to stand out in a crowded marketplace. Many devices targeting the same patient demographics provide comparable functionalities, which has led to price wars, where manufacturers reduce their prices to attract customers. While this may benefit patients in terms of affordability, it erodes profit margins and limits the ability of manufacturers to reinvest in product innovation. Smaller or newer companies often find it particularly difficult to compete against well-established players with greater resources for marketing, distribution, and research and development. These larger companies can leverage their brand recognition, extensive distribution networks, and financial strength to dominate the market, leaving less room for smaller firms to grow. The competition also limits the ability of newer players to achieve economies of scale, further hindering their ability to offer competitive pricing.

The lack of significant differentiation between treatment devices further complicates purchasing decisions for healthcare providers and patients. Many products in the market offer similar therapeutic benefits, and without clear distinctions in terms of features, effectiveness, or usability, both patients and providers may struggle to select the most appropriate device. This confusion can delay the adoption of innovative products, impacting overall market growth and reducing the pace at which advancements reach the patient population.

Key Market Trends

Increasing Investments in Research and Development

Increasing investments in research and development (R&D) are driving significant advancements in the global market for stress urinary incontinence (SUI) treatment devices. Medical device companies are allocating substantial resources to innovate and improve existing technologies, focusing on enhancing patient outcomes and addressing unmet clinical needs. This commitment to R&D is fueling the development of devices that are safer, more effective, and tailored to individual patient requirements. For instance, The study titled "Randomized Trial of Mechanotherapy for the Treatment of Stress Urinary Incontinence in Women" validates the efficacy of the FDA-cleared Flyte device. The findings show significant improvements in women with stress urinary incontinence (SUI) and weakened pelvic floor muscles. Conducted as a double-blind, controlled trial with 119 participants, it is one of the largest studies examining in-home SUI treatments. Notably, 71% of participants achieved dryness or near dryness during the treatment period, with lasting improvements in quality of life over two years. This research builds on prior studies from the Arctic University of Norway, where Flyte demonstrated a high success rate in addressing long-term SUI symptoms, often reducing the need for surgical intervention.

A key area of focus in R&D is the improvement of sling materials used in surgical treatments. Innovations in biocompatible, lightweight meshes are reducing complications such as infection and tissue erosion while improving patient comfort and long-term outcomes. Simultaneously, advancements in electrical stimulation devices are enabling more precise targeting of pelvic floor muscles, leading to improved treatment efficacy and increased patient satisfaction. These technological breakthroughs are critical in expanding non-surgical options, particularly for women seeking minimally invasive solutions.

Collaborative efforts between medical device manufacturers, academic institutions, and healthcare providers are further accelerating innovation. These partnerships facilitate the development of next-generation devices by combining clinical insights with engineering expertise. Customizable solutions tailored to diverse patient anatomies and conditions are emerging as a direct result of these joint initiatives, making treatment options more inclusive and effective. R&D investments are also addressing safety concerns and reducing device-related complications, which are pivotal factors influencing patient and provider choices. By improving the safety profile of treatment devices, companies are fostering greater trust and adoption among healthcare professionals and patients alike. The drive for regulatory approvals of advanced devices is enhancing market penetration across regions. Once approved, these innovations not only strengthen the competitive position of manufacturers but also provide patients with access to cutting-edge solutions. This steady pipeline of new products ensures the market remains dynamic, responsive, and aligned with the evolving needs of women affected by SUI, further propelling its growth globally.

Expanding Healthcare Infrastructure in Emerging Markets

The expansion of healthcare infrastructure in emerging markets such as Asia-Pacific, Latin America, and the Middle East is significantly driving the demand for stress urinary incontinence (SUI) treatment devices. Governments and private sector entities in these regions are investing heavily in modernizing healthcare systems, resulting in improved access to advanced diagnostic and therapeutic solutions. These efforts are bridging the gap between healthcare facilities in urban and rural areas, allowing more women to seek timely and effective treatment for SUI.

One key factor contributing to this growth is the rising awareness of SUI and its impact on quality of life. Enhanced healthcare outreach programs, often supported by public-private partnerships, are educating women about SUI and the importance of early intervention. Simultaneously, physician training initiatives are equipping healthcare providers with the knowledge and skills to recommend and administer advanced treatment options. These efforts are normalizing discussions around SUI, reducing stigma, and encouraging women to seek professional care. The economic transformation in countries like China, India, and Brazil is another critical driver. The growing middle-class population in these regions, coupled with rising disposable incomes, has significantly improved affordability for medical treatments. As a result, more women are able to access advanced SUI treatment devices, including minimally invasive surgical solutions and non-invasive therapies such as electrical stimulation systems.

For device manufacturers, these developments present lucrative opportunities to expand their footprint in high-potential markets. By establishing local partnerships, investing in region-specific product development, and aligning with government initiatives, companies can effectively address the unique needs of these diverse populations. The increasing adoption of digital health technologies in these regions is further facilitating access to information and treatment, creating a favorable environment for market growth. The combination of improved infrastructure, growing awareness, and economic advancements is transforming emerging markets into critical hubs for the SUI treatment devices market, contributing significantly to its global expansion.

Segmental Insights

Product Type Insights

Based on the Product Type, Among the product types available in the global female stress urinary incontinence (SUI) treatment devices market, urethral slings are currently the dominant segment. Urethral slings are considered the gold standard for surgical intervention in the treatment of moderate to severe stress urinary incontinence. These devices are designed to support the urethra, providing a lifting effect that helps prevent urine leakage during physical activities, such as coughing, sneezing, or exercising. The popularity of urethral slings is driven by their high effectiveness and long-term results compared to other treatment options. One of the key factors contributing to the dominance of urethral slings is their well-established clinical outcomes. Numerous studies and clinical trials have demonstrated their efficacy in providing significant relief from SUI symptoms, leading to widespread adoption by healthcare professionals. The advancement of sling materials, such as synthetic meshes, has improved the safety profile and ease of implantation, further driving their use in clinical practice.

Urethral slings are also favored for their relatively low recurrence rates and the ability to restore normal bladder function, which appeals to both patients and healthcare providers. As a result, they are the first-line surgical treatment recommended for patients with severe cases of stress urinary incontinence who do not respond to conservative measures like pelvic floor exercises or non-invasive devices.

Regional Insights

North America is expected to dominate the global female stress urinary incontinence (SUI) treatment devices market during the forecast period. This dominance is largely driven by the high prevalence of SUI in the region, combined with well-established healthcare infrastructure and significant advancements in medical technologies. In North America, particularly the United States, there is increasing awareness and diagnosis of female SUI, which has led to a growing demand for effective treatment options. The region benefits from a large number of healthcare providers specializing in urology and gynecology, which ensures that patients have access to the latest and most effective treatment devices. Hospitals and ambulatory surgical centers (ASCs) in North America are highly equipped with state-of-the-art medical devices, allowing them to offer a wide range of both non-surgical and surgical SUI treatments, such as urethral slings and electrical stimulation devices.

The high adoption rate of advanced treatment options, especially surgical procedures like sling placements, further drives market growth in the region. North America's relatively high healthcare expenditure, strong reimbursement policies, and favorable regulatory environment for medical devices contribute to the overall market expansion. The rising focus on patient-centric care and the growing shift toward outpatient and minimally invasive procedures also play a key role in propelling market growth.

Key Market Players

Johnson & Johnson
Caldera Medical Inc
B. Braun Medical Limited
Becton, Dickinson and Company
CooperSurgical Inc.
MedGyn Products, Inc
Boston Scientific Corporation
Atlantic Therapeutics
Coloplast Corp.
Convatec Inc.

Report Scope:

In this report, the Global Female Stress Urinary Incontinence Treatment Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Female Stress Urinary Incontinence Treatment Devices Market, By Product Type:

Urethral Slings
Catheters
Vaginal Pessaries
Others

Female Stress Urinary Incontinence Treatment Devices Market, By End-user:

Hospitals & Ambulatory Surgical Centers (ASCs)
Specialty Clinics
Others

Female Stress Urinary Incontinence Treatment Devices Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Female Stress Urinary Incontinence Treatment Devices Market.

Available Customizations:

Global Female Stress Urinary Incontinence Treatment Devices Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Female Stress Urinary Incontinence Treatment Devices Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Product Type (Urethral Slings, Catheters, Vaginal Pessaries, and Others)
- 5.2.2. By End-user (Hospitals & Ambulatory Surgical Centers (ASCs), Specialty Clinics, and Others)
- 5.2.3. By Company (2023)
- 5.2.4. By Region
5.3. Market Map

6. North America Female Stress Urinary Incontinence Treatment Devices Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Product Type
- 6.2.2. By End-user
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Product Type
    - 6.3.1.2.2. By End-user
- 6.3.2. Mexico Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Product Type
    - 6.3.2.2.2. By End-user
- 6.3.3. Canada Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Product Type
    - 6.3.3.2.2. By End-user

7. Europe Female Stress Urinary Incontinence Treatment Devices Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Product Type
- 7.2.2. By End-user
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Product Type
    - 7.3.1.2.2. By End-user
- 7.3.2. Germany Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Product Type
    - 7.3.2.2.2. By End-user
- 7.3.3. United Kingdom Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Product Type
    - 7.3.3.2.2. By End-user
- 7.3.4. Italy Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Product Type
    - 7.3.4.2.2. By End-user
- 7.3.5. Spain Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Product Type
    - 7.3.5.2.2. By End-user

8. Asia-Pacific Female Stress Urinary Incontinence Treatment Devices Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Product Type
- 8.2.2. By End-user
- 8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Product Type
    - 8.3.1.2.2. By End-user
- 8.3.2. India Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Product Type
    - 8.3.2.2.2. By End-user
- 8.3.3. South Korea Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Product Type
    - 8.3.3.2.2. By End-user
- 8.3.4. Japan Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Product Type
    - 8.3.4.2.2. By End-user
- 8.3.5. Australia Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Product Type
    - 8.3.5.2.2. By End-user

9. South America Female Stress Urinary Incontinence Treatment Devices Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Product Type
- 9.2.2. By End-user
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Product Type
    - 9.3.1.2.2. By End-user
- 9.3.2. Argentina Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Product Type
    - 9.3.2.2.2. By End-user
- 9.3.3. Colombia Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Product Type
    - 9.3.3.2.2. By End-user

10. Middle East and Africa Female Stress Urinary Incontinence Treatment Devices Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Product Type
- 10.2.2. By End-user
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Product Type
    - 10.3.1.2.2. By End-user
- 10.3.2. Saudi Arabia Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Product Type
    - 10.3.2.2.2. By End-user
- 10.3.3. UAE Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Product Type
    - 10.3.3.2.2. By End-user

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Porters Five Forces Analysis

13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products

14. Competitive Landscape

14.1. Johnson & Johnson
- 14.1.1. Business Overview
- 14.1.2. Company Snapshot
- 14.1.3. Products & Services
- 14.1.4. Financials (As Reported)
- 14.1.5. Recent Developments
- 14.1.6. Key Personnel Details
- 14.1.7. SWOT Analysis
14.2. Caldera Medical Inc
14.3. B. Braun Medical Limited
14.4. Becton, Dickinson and Company
14.5. CooperSurgical Inc.
14.6. MedGyn Products, Inc
14.7. Boston Scientific Corporation
14.8. Atlantic Therapeutics
14.9. Coloplast Corp.
14.10. Convatec Inc.